

www.acsami.org Research Article

Tea Polyphenol Liposomes Overcome Gastric Mucus to Treat Helicobacter Pylori Infection and Enhance the Intestinal Microenvironment

Guiyun Deng, Yang Wu, Zhiyong Song, Shuojun Li, Moqing Du, Jiamin Deng, Quan Xu, Liu Deng, Hagar Shendy Bahlol, and Heyou Han*



Cite This: ACS Appl. Mater. Interfaces 2022, 14, 13001-13012




ACCESS

Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: Infection with *Helicobacter pylori* (*Hp*) is one of the leading causes of stomach cancer. The ability to treat *Hp* infection is hampered by a lack of stomach gastric acid environment. This work introduces a nanoliposome that can rapidly adjust the gastric acid environment to ensure a drug's optimal efficacy. We introduce CaCO₃@Fe-TP@EggPC nanoliposomes (CTE NLs) that are composed of Fe³⁺ and tea polyphenols (TPs) forming complexes on the surface of internal CaCO₃ and then with lecithin producing a phospholipid bilayer on the polyphenols' outer surface. Through the action of iron-TP chelate, the phospholipid layer can fuse with the bacterial membrane to eliminate *Hp*. Furthermore, CaCO₃ can promptly consume the excessive gastric acid, ensuring an ideal operating environment for the chelate. TPs, on the other hand, can improve the inflammation and gut microbes in the body. The experimental results show that CTE NLs can quickly consume protons in the stomach and reduce the bacterial burden by 1.2 orders of magnitude while reducing the inflammatory



factors in the body. The biosafety evaluation revealed that nanoliposomes have good biocompatibility and provide a new strategy for treating Hp infection.

KEYWORDS: Hp infection, nanoliposomes, tea polyphenols, neutralize stomach acid, reduce inflammatory factors

INTRODUCTION

Helicobacter pylori (Hp) is a Gram-negative bacterial pathogen that colonizes about 50% of the world's population and is a risk factor for developing gastric/duodenal ulcers and gastric cancer. The urease produced by Hp can hydrolyze urea, creating a protective layer of ammonia cloud around the bacteria to resist the adverse effects of gastric acid on Hp. In addition, HP's acid resistance and ability to neutralize acids making it resilient in acidic environments, which is also considered to be a critical factor in destroying gastric mucosal cells. The injury of the gastric mucosa destroys the mucus—bicarbonate barrier and intensifies the erosion of gastric acid and pepsin on the mucosa, forming a vicious circle. Furthermore, Hp infection increases inflammatory factors and causes gastric tissue lesions (Scheme 1).

Due to the rising resistance to current antibiotics, the demand for new therapeutic agents that can prevent the occurrence and development of diseases has not been satisfied. The current clinical trials of Hp rely on at least two antibiotics (clarithromycin, amoxicillin, or metronidazole, etc.) and proton pump inhibitors (PPIs). Unfortunately, the Hp mutation has evolved into resistance to clarithromycin and other macrolide medications, resulting in a high proportion of

treatment failures. Therefore, the *Hp* eradication rate with a standard triple therapy has dropped significantly. On the other hand, long-term treatment is associated with adverse effects such as antibiotic resistance, reinfection, high cost, gastrointestinal side effects, and poor patient compliance.^{7,8} Currently, alternative drugs and treatments for the drug resistance are being actively studied. Therefore, there is an urgent need for new methods to overcome these limitations.

Since ancient times, tea has been recognized as a traditional Chinese medicine that can improve or prevent various diseases. Recent research has revealed that tea polyphenols (TPs), including epigallocatechin (EGC), epicatechin gallate (ECG), epigallocatechin gallate (EGCG), and tannic acid (TA), have antibacterial and anticancer properties. Natural polyphenols have recently received widespread attention due to their surface adaptability and interfacial adhesion, as well as

Received: December 2, 2021 Accepted: February 28, 2022 Published: March 10, 2022



